<DOC>
	<DOCNO>NCT01312766</DOCNO>
	<brief_summary>The purpose non-inferiority study evaluate clinical efficacy safety two different subcutaneous hMG preparation administer patient undergo controlled ovarian stimulation IVF .</brief_summary>
	<brief_title>Safety Efficacy Study Vitro Fertilisation ( IVF ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Infertility</mesh_term>
	<criteria>Women undergo ovarian stimulation IVF follow characteristic : Able willing sign Patient Consent Form adhere study visitation schedule &gt; 18 &lt; 40 year old BMI 18 30 kg/m2 less 3 previously complete IVF cycle ( i.e . complete cycle = egg recovery ) basal FSH &lt; 10 IU/L E2 &lt; 80 pg/ml ( ~290 pmol/l ) Within 12 month begin study , uterine cavity consistent expect normal function assess transvaginal ultrasound , hysterosalpingogram , sonohysterogram hysteroscopic examination Successful downregulation perform standard GnRHAgonist long protocol ( Criteria successful downregulation : endometrial thickness &lt; 7mm serum E2 level &lt; 50 pg/ml ( ~185 pmol/l ) . age &lt; 18 &gt; 40 year primary ovarian failure woman know poor responder ( i.e . require 225 IU hMG start dose previous treatment cycle less 3 oocyte retrieve , preovulatory E2 serum concentration &lt; 500pg/ml ( ~1800 pmol/l ) ) PCOS one ovaries inaccessible oocyte retrieval ovarian cyst &gt; 10 mm hydrosalpinx surgically remove ligate ; stage 3 4 endometriosis oocyte donation implantation previously frozen embryo patient affected pathology associate contraindication pregnant hypersensitivity study medication abnormal bleed undetermined origin uncontrolled thyroid adrenal dysfunction neoplasia severe impairment renal and/or hepatic function use concomitant medication might interfere study evaluation ( e.g . nonstudy hormonal medication , prostaglandin inhibitor , psychotropic agent )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>